Heron Therapeutics (HRTX) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 8 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Heron Therapeutics (HRTX) : The highest level Heron Therapeutics (HRTX) is projected to reach is $55 for the short term and the lowest estimate is at $33. The consolidated price target from 8 rating analysts who initiate coverage on the stock is $43.75 and the possibility the share price can swing is $7.01.
Also, Equity Analysts at the Brokerage Firm, Lake Street, assumes their rating on the shares of Heron Therapeutics (NASDAQ:HRTX). Lake Street has a Buy rating on the shares. As per the latest report, the brokerage house announces the price target to $45 per share. The rating by the firm was issued on September 6, 2016.
Heron Therapeutics (NASDAQ:HRTX): The stock opened in the green at $19.7 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $19.7 and a low of $18.7 for the day. The stock did not find buyers even at the lows and closed at $19.49 recording a loss of -0.71%. 515,664 shares exchanged hands during the trading day. The stock had closed at $19.63 in the previous days trading.
Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Companys product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Companys product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Companys other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.